These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36598365)

  • 1. HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype.
    Xu M; Sun M; Zhang X; Nguyen R; Lei H; Shern JF; Thiele CJ; Liu Z
    Cancer Res; 2023 Mar; 83(5):686-699. PubMed ID: 36598365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry.
    Durbin AD; Zimmerman MW; Dharia NV; Abraham BJ; Iniguez AB; Weichert-Leahey N; He S; Krill-Burger JM; Root DE; Vazquez F; Tsherniak A; Hahn WC; Golub TR; Young RA; Look AT; Stegmaier K
    Nat Genet; 2018 Sep; 50(9):1240-1246. PubMed ID: 30127528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry.
    Wang L; Tan TK; Durbin AD; Zimmerman MW; Abraham BJ; Tan SH; Ngoc PCT; Weichert-Leahey N; Akahane K; Lawton LN; Rokita JL; Maris JM; Young RA; Look AT; Sanda T
    Nat Commun; 2019 Dec; 10(1):5622. PubMed ID: 31819055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma.
    Tan K; Mo J; Li M; Dong Y; Han Y; Sun X; Ma Y; Zhu K; Wu W; Lu L; Liu J; Zhao K; Zhang L; Tang Y; Lv Z
    J Exp Clin Cancer Res; 2022 Dec; 41(1):352. PubMed ID: 36539767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA SNHG1 regulates neuroblastoma cell fate via interactions with HDAC1/2.
    Hsu CL; Yin CF; Chang YW; Fan YC; Lin SH; Wu YC; Huang HC; Juan HF
    Cell Death Dis; 2022 Sep; 13(9):809. PubMed ID: 36130928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis.
    Murray JE; Valli E; Milazzo G; Mayoh C; Gifford AJ; Fletcher JI; Xue C; Jayatilleke N; Salehzadeh F; Gamble LD; Rouaen JRC; Carter DR; Forgham H; Sekyere EO; Keating J; Eden G; Allan S; Alfred S; Kusuma FK; Clark A; Webber H; Russell AJ; de Weck A; Kile BT; Santulli M; De Rosa P; Fleuren EDG; Gao W; Wilkinson-White L; Low JKK; Mackay JP; Marshall GM; Hilton DJ; Giorgi FM; Koster J; Perini G; Haber M; Norris MD
    Nat Commun; 2024 Jul; 15(1):5585. PubMed ID: 38992040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
    Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
    Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
    Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
    Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.
    Zeid R; Lawlor MA; Poon E; Reyes JM; Fulciniti M; Lopez MA; Scott TG; Nabet B; Erb MA; Winter GE; Jacobson Z; Polaski DR; Karlin KL; Hirsch RA; Munshi NP; Westbrook TF; Chesler L; Lin CY; Bradner JE
    Nat Genet; 2018 Apr; 50(4):515-523. PubMed ID: 29379199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.
    Rajbhandari P; Lopez G; Capdevila C; Salvatori B; Yu J; Rodriguez-Barrueco R; Martinez D; Yarmarkovich M; Weichert-Leahey N; Abraham BJ; Alvarez MJ; Iyer A; Harenza JL; Oldridge D; De Preter K; Koster J; Asgharzadeh S; Seeger RC; Wei JS; Khan J; Vandesompele J; Mestdagh P; Versteeg R; Look AT; Young RA; Iavarone A; Lasorella A; Silva JM; Maris JM; Califano A
    Cancer Discov; 2018 May; 8(5):582-599. PubMed ID: 29510988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
    Aygun N; Altungoz O
    Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYCN Directly Targets NeuroD1 to Promote Cellular Proliferation in Neuroblastoma.
    Lu F; Mu B; Jin G; Zhu L; Mu P
    Oncol Res; 2022 May; 29(1):1-10. PubMed ID: 34937609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene or
    Bhardwaj N; Das G; Srinivasan R
    J Clin Pathol; 2023 Aug; 76(8):518-523. PubMed ID: 37221048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYCN-induced E2F5 promotes neuroblastoma cell proliferation through regulating cell cycle progression.
    Liu Y; Liu D; Wan W
    Biochem Biophys Res Commun; 2019 Mar; 511(1):35-40. PubMed ID: 30765227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
    Newman EA; Chukkapalli S; Bashllari D; Thomas TT; Van Noord RA; Lawlor ER; Hoenerhoff MJ; Opipari AW; Opipari VP
    Cell Death Dis; 2017 Dec; 8(12):3208. PubMed ID: 29238067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
    Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
    Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
    Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF
    Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
    Chen L; Alexe G; Dharia NV; Ross L; Iniguez AB; Conway AS; Wang EJ; Veschi V; Lam N; Qi J; Gustafson WC; Nasholm N; Vazquez F; Weir BA; Cowley GS; Ali LD; Pantel S; Jiang G; Harrington WF; Lee Y; Goodale A; Lubonja R; Krill-Burger JM; Meyers RM; Tsherniak A; Root DE; Bradner JE; Golub TR; Roberts CW; Hahn WC; Weiss WA; Thiele CJ; Stegmaier K
    J Clin Invest; 2018 Jan; 128(1):446-462. PubMed ID: 29202477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
    Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.